KS-KCAS
KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners, closed the purchase of Active Biomarkers, located in Lyon, France. Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders. Financial terms were not disclosed. Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities. This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries. The acquisition of Active Biomarkers is the second in 2022 by KCAS. FlowMetric, a leading flow cytometry and cellular analysis CRO, joined KCAS in early 2022. The Lyon site adds to KCAS and FlowMetric’s existing facilities in Kansas, Philadelphia and Milan, Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005063/en/
Active Biomarkers building in Lyon, France (Photo: Business Wire)
John Bucksath, CEO of KCAS, stated “We are delighted to partner with the Active Biomarkers team, accelerating our combined offering to support the customers we serve globally. The combined expertise and capacity of KCAS, FlowMetric, and Active Biomarkers is unique. The high-quality, science-first and client-centric culture we all share is key to our commitment to become the CRO partner of choice for the global pharma and biopharma industries. KCAS has embarked on significant investments, including a purpose-built 70,000 sq. ft. facility in Kansas City and a 26,000 sq. ft. facility in Pennsylvania, and accelerating our international footprint through acquisitions. We continue to attract the industry’s top scientific talent and focus on outstanding science and customer service. With our investors, Vitruvian Partners, we are optimally positioned to invest in our people and deliver world-class services for our growing client base. The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.”
Marc Essodaigui, CEO of Active Biomarkers, comments, “Our entire team is thrilled about the new partnership with KCAS and the combined organizations’ outlook. This combination will allow us to provide even more comprehensive, best-in-class services for the biopharma and life sciences sector. The KCAS’ alliance, backed by a leading world-class growth investor, will provide us with the support and growth to expand our technological expertise, capacity, and geographical footprint.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, comments, “Active Biomarkers has built a strong reputation in Europe founded in scientific excellence. The company fits with our investment strategy of backing best-in-class operations offering services to a market with strong tailwinds and internationalization opportunities. The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the company’s growing pharmaceutical and biotech clients. As the drug development market continues to evolve, we will continue to support investment in scientific capabilities, broadening geographical reach, providing the resources to scale the business, and making strategic acquisitions.”
About KCAS - KCAS is a rapidly growing company that provides comprehensive GLP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS is headquartered in Olathe, Kansas – the Kansas City metro area and employs more than 300 employees. Website: KCASBio.com.
About Active Biomarkers – Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in state-of-the-art BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms. Website: active-biomarkers.com
About Vitruvian - Vitruvian is a leading international growth investor headquartered in London with additional offices in Stockholm, Madrid, Munich, Luxembourg, San Francisco, Singapore and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 90 companies and has assets under management of approximately €10 billion. Website: vitruvianpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Unveils Advanced Matter over Thread Modules for Seamless Device Interoperability13.11.2025 10:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announced the launch of the KGM133S, the first in a range of Matter over Thread modules that provides innovative solutions for applications such as smart door locks, sensors, and lighting, helping the smart home industry overcome connectivity barriers and advance toward a new era of more efficient and seamless development. The KGM133S series modules are built based on the Silicon Labs EFR32MG24 chip, supporting the latest Matter 1.4 protocol. The modules are designed to enable seamless linkage of home devices across ecosystems, including Apple Home, Google Home, Amazon Alexa and Samsung SmartThings. “Protocol fragmentation remains one of the biggest obstacles to seamless smart device connectivity, and the Matter protocol is the key to overcoming it,” said Delbert Sun, Deputy General Manager at Quectel Wireless Solutions. “With our new Matter over Thread modules, we are helping the industry achieve true inter
SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 09:57:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).
IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 09:56:00 CET | Press release
IQM Halocene is a new quantum computer product line aimed at error correction development. It will start with a150-qubit system to be delivered by the end of 2026 and extend all the way to 1,000-qubits. The new product line is based on an open and modular error correction stack, which will allow end-users to experiment and run different quantum error correction features. IQM’s goal is to enable users from supercomputing centers, research organizations, and universities to innovate on quantum error correction research with an open platform. IQM has sold more on-premises quantum systems globally than any other manufacturer, and the company expects the new Halocene product line to accelerate its revenue growth further IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research
JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 09:45:00 CET | Press release
Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discover
Ohmium Breaks Barriers: Exceeds 2030 Industry Targets of 10 GW/ton to Achieve 18 GW/ton Iridium Utilization13.11.2025 09:05:00 CET | Press release
Ohmium International Inc., a leading provider of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has surpassed the PEM electrolyzer industry's 2030 target of 10 GW per ton to attain an 18 GW per ton iridium utilization rate. Ohmium has made significant technological advancements which have resulted in reducing its iridium usage by 50% in its Lotus electrolyzer, Mark 2. This enhances the cost-competitiveness of green hydrogen production by reducing the overall cost of its PEM electrolyzers, which have been impacted by the cost of the precious metal, iridium. Dr. Chock Karuppaiah, Ohmium Chief Science and Technology Officer, said, "We've made significant strides in reducing iridium usage in our PEM electrolyzers, exceeding the 2030 industry target of 10 GW per ton. We've achieved a utilization rate of 18 GW per ton. This innovation is crucial, as iridium is one of the most expensive materials in electrolyzer manufacturing.” Dr. Markus Tacke, Ohmiu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom